A Combined Approach with Rituximab Plus Anti-TRAIL-R Agonistic Antibodies for the Treatment of Haematological Malignancies

Publisher： Bentham Science Publishers

E-ISSN： 1873-4286|14|21|2085-2099

ISSN： 1381-6128

Source： Current Pharmaceutical Design, Vol.14, Iss.21, 2008-07, pp. : 2085-2099

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Advances in the treatment for haematological malignancies

By Piccaluga Pier Paolo   Martinelli Giovanni   Baccarani Michele  

Expert Opinion on Pharmacotherapy, Vol. 7, Iss. 6, 2006-04 ,pp. : 721-732

Informa Healthcare

Access to resources Recommend Favorite

Arsenic trioxide in the treatment of haematological malignancies

By Kwong Yok-Lam  

Expert Opinion on Drug Safety, Vol. 3, Iss. 6, 2004-11 ,pp. : 589-597

Informa Healthcare

Access to resources Recommend Favorite

Nucleoside analogues in the treatment of haematological malignancies

By Johnson Stephen A  

Expert Opinion on Pharmacotherapy, Vol. 2, Iss. 6, 2001-06 ,pp. : 929-943

Informa Healthcare

Access to resources Recommend Favorite

Cytokines as Anti-Angiogenic Agents in Haematological Malignancies

By  

Current Cancer Drug Targets, Vol. 11, Iss. 9, 2011-11 ,pp. : 997-1004

Bentham Science Publishers

Access to resources Recommend Favorite

TNF-Related Apoptosis-Inducing Ligand (TRAIL): A Potential Candidate for Combined Treatment of Hematological Malignancies

By  

Current Pharmaceutical Design, Vol. 10, Iss. 29, 2004-11 ,pp. : 3673-3681

Bentham Science Publishers

Access to resources Recommend Favorite